Neurocrine Biosciences | NBIX - Selling And Administration Expenses


Neurocrine Biosciences reported $383.1M in Selling and Administration Expenses for its fiscal quarter ending in June of 2026.





Selling And Administration Expenses Change Date
AbbVie USD 3.63B 54M Jun/2026
Acadia Pharmaceuticals USD 148.57M 12.22M Jun/2026
Agios Pharmaceuticals USD 38.46M 4.51M Mar/2026
ALKERMES USD 196.64M 67.96M Jun/2026
Alnylam Pharmaceuticals USD 347.92M 65.41M Jun/2026
Amgen USD 1.72B 134M Jun/2026
Biogen USD 709.7M 155.4M Jun/2026
BioMarin Pharmaceutical USD 258.28M 63.92M Mar/2026
Cytokinetics USD 104.9M 13.17M Mar/2026
Enanta Pharmaceuticals USD -1.05 0.31 Dec/2024
Exelixis USD 139.6M 16.58M Mar/2026
Gilead Sciences USD 1.52B 70M Jun/2026
Halozyme Therapeutics USD 46.29M 18.35M Mar/2026
Incyte USD 351.73M 23.64M Jun/2026
Ionis Pharmaceuticals USD 130.07M 20.92M Jun/2026
Nektar Therapeutics USD 11.87M 1.7M Mar/2026
Neurocrine Biosciences USD 383.1M 64.6M Jun/2026
Pfizer USD 3.41B 496M Jun/2026
Prothena USD 12.67M 5.02M Mar/2026
Regeneron Pharmaceuticals USD 662.1M 14.4M Jun/2026
Repligen USD 76.62M 82K Jun/2026
Rigel Pharmaceuticals USD 27.04M 1M Sep/2024
Sarepta Therapeutics USD 54.03M 51.35M Mar/2026
Teva Pharmaceutical Industries USD 1.03B 34M Jun/2026
Ultragenyx Pharmaceutical USD 88M 1000K Mar/2026
Vertex Pharmaceuticals USD 582.2M 88.5M Jun/2026